Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for schizophrenia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Lumateperone tosylate (Caplyta) - schizophrenia Drug Approval Package: CAPLYTA CAPLYTA " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: CAPLYTA Company: Intra-Cellular Therapies, Inc Application Number: 209500 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Treatment of Patients with Schizophrenia This guideline is undergoing copyediting and the final version is expected to be released summer 2020. THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA Guideline Writing Group George A. Keepers, M.D. (Chair) Laura J. Fochtmann, M.D., M.B.I. (Vice-Chair; Methodologist) Joan M. Anzia, M.D. Sheldon Benjamin, M.D. Jeffrey M. Lyness, M.D. Ramin Mojtabai, M.D. Mark Servis, M.D. Art Walaszek, M.D. Peter (...) Schizophrenia 18 Implementation 18 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 31 Review of Available Guidelines from Other Organizations 32 Quality Measurement Considerations 32 Statement 2: Use of Quantitative Measures 33 Implementation 33 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 36 Review of Available Guidelines from Other Organizations 38 Quality Measurement Considerations 38 Statement 3: Evidence-based
Evidence-based guidelines for the pharmacological treatment of schizophrenia The British Association for Psychopharmacology | BAP Consensus Guidelines – Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Email Address: Password: Keep me logged in for 24 hours | Menu About Us Join BAP Members' Area Publications Meetings Education and Training Prizes and Awards Prizes and Awards Bursaries (...) > > Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Please note that COPYRIGHT in the paper is owned by the British Association for Psychopharmacology (BAP). SINGLE ISSUE USE ONLY (and printing) for PERSONAL RESEARCH ONLY is acceptable. Information
Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear.To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients (...) with schizophrenia and predominant negative symptoms.The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included.Ten sessions of tDCS performed twice
Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia (...) or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: January 3, 2019 Project Number: RC1053-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients with schizophrenia or bipolar disorder? What is the cost-effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Schizophrenia is one of the most common, burdensome, and costly psychiatric disorders in adults worldwide. Antipsychotic drugs are its treatment of choice, but there is controversy about which agent should be used. We aimed to compare and rank antipsychotics by quantifying information from randomised controlled (...) of schizophrenia or related disorders. We excluded studies in patients with treatment resistance, first episode, predominant negative or depressive symptoms, concomitant medical illnesses, and relapse-prevention studies. Our primary outcome was change in overall symptoms measured with standardised rating scales. We also extracted data for eight efficacy and eight safety outcomes. Differences in the findings of the studies were explored in metaregressions and sensitivity analyses. Effect size measures were
Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS
Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental illnesses. People with catatonia are more likely to require hospitalisation and highly supervised care than those without the disorder. They also have an increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug (...) therapies and electroconvulsive therapy.To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for catatonia in people with schizophrenia or other similar serious mental illnesses (SMIs).We updated our previous search (28 February 2007) by searching the Cochrane Schizophrenia Group's Study-Based Register of Trials (9 November 2016; 6 February 2019). This register is compiled by systematic searches of major resources (including CENTRAL, MEDLINE, Embase, AMED
Brexpiprazole (Rxulti) for the treatment of schizophrenia in adults Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults | Report | National Health Care Institute You are here: Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Search within English part of National Health Care Institute Search Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti® (...) ) can be accepted into the Medicine Reimbursement System (GVS). Registration Brexpiprazole (Rxulti®), an antipsychotic, is registered and indicated for the treatment of schizophrenia in adults. Zorginstituut's advice Based on the criteria for interchangeability, we conclude that brexpiprazole (Rzulti®) is interchangeable with the other drugs in GVS cluster N405AXAO V, which includes: aripiprazole, cariprazine, paliperidone, quetiapine and risperidone. A standard dose of 3 mg can be established
Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Schizophrenia is a leading cause of disability, and a shift from facility- to community-based care has been proposed to meet the resource challenges of mental healthcare in low- and middle-income countries. We hypothesized that the addition of mobile texting would improve (...) schizophrenia care in a resource-poor community setting compared with a community-based free-medicine program alone.In this 2-arm randomized controlled trial, 278 community-dwelling villagers (patient participants) were randomly selected from people with schizophrenia from 9 townships of Hunan, China, and were randomized 1:1 into 2 groups. The program participants were recruited between May 1, 2015, and August 31, 2015, and the intervention and follow-up took place between December 15, 2015, and July 1
Cariprazine (Reagila) for the treatment of schizophrenia in adult patients. 1 Published 13 May 2019 1 SMC2137 cariprazine 1.5mg, 3mg, 4.5mg and 6mg hard capsules (Reagila®) Recordati Pharmaceuticals Ltd 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission cariprazine (Reagila® (...) ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of schizophrenia in adult patients. SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature. In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic. Chairman Scottish Medicines Consortium www.scottishmedicines.or g.uk 2
Haloperidol discontinuation for people with schizophrenia. Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews.To review the effects of haloperidol discontinuation (...) in people with schizophrenia who are stable on haloperidol.On 20 February 2015, 24 May 2017, and 12 January 2019, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including trial registers.We included clinical trials randomising adults with schizophrenia or related disorders who were receiving haloperidol, and were stable. We included trials that randomised such participants to either continue their current treatment with haloperidol or discontinue their haloperidol
Yoga as part of a package of care versus non-standard care for schizophrenia. Yoga is an ancient body-mind practice which originated in India and is popular in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine the efficacy of yoga delivered as a package of care versus non-standard care.To examine the effects of yoga as part of a package of care versus non-standard care for schizophrenia.We searched the Cochrane (...) Schizophrenia Group Trials Register (latest 15 May 2018) which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSS, AMED, PsychINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga as part of a package of care with non-standard care.There were
Peer support for people with schizophrenia or other serious mental illness. Peer support provides the opportunity for peers with experiential knowledge of a mental illness to give emotional, appraisal and informational assistance to current service users, and is becoming an important recovery-oriented approach in healthcare for people with mental illness.To assess the effects of peer-support interventions for people with schizophrenia or other serious mental disorders, compared to standard care (...) or other supportive or psychosocial interventions not from peers.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials on 27 July 2016 and 4 July 2017. There were no limitations regarding language, date, document type or publication status.We selected all randomised controlled clinical studies involving people diagnosed with schizophrenia or other related serious mental illness that compared peer support to standard care or other psychosocial interventions and that did
Electroconvulsive therapy for treatment-resistant schizophrenia. Electroconvulsive therapy (ECT) involves the induction of a seizure by the administration of an electrical stimulus via electrodes usually placed bilaterally on the scalp and was introduced as a treatment for schizophrenia in 1938. However, ECT is a controversial treatment with concerns about long-term side effects such a memory loss. Therefore, it is important to determine its clinical efficacy and safety for people (...) with schizophrenia who are not responding to their treatment.Our primary objective was to assess the effects (benefits and harms) of ECT for people with treatment-resistant schizophrenia.Our secondary objectives were to determine whether ECT produces a differential response in people: who are treated with unilateral compared to bilateral ECT; who have had a long (more than 12 sessions) or a short course of ECT; who are given continuation or maintenance ECT; who are diagnosed with well-defined treatment-resistant
Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Discover Portal Discover Portal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 doi: For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug clozapine, adding amisulpride (another (...) particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007, approximately 30% of the total
Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment CBT and treatment resistant schizophrenia Discover Portal Discover Portal Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment Published on 20 November 2018 doi: Cognitive behavioural therapy (CBT) does not improve residual symptoms for people taking clozapine for schizophrenia. Clozapine is the gold (...) -standard antipsychotic that is used when others have not worked. This NIHR-funded UK trial included 487 adults who had been taking clozapine for on average five years but were still symptomatic. Participants received either weekly CBT for nine months alongside usual treatment for schizophrenia or usual treatment alone. Usual treatment included clozapine or other medication and care from secondary, community or inpatient mental health services. There were no differences in favour of CBT at the main time
Monocytes in schizophrenia spectrum disorders: a comparative meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect
Efficacy and tolerability of antibiotic augmentation in schizophrenia spectrum disorders - a systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence
A systematic review comparing caregiver's burden and psychological impacts in caregivers of individuals with schizophrenia spectrum disorders and bipolar disorders Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g